The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
Open accessAbstract
PPARgamma is a ligand-activated transcription factor and functions as a heterodimer with a retinoid X receptor (RXR). Supraphysiological activation of PPARgamma by thiazolidinediones can reduce insulin resistance and hyperglycemia in type 2 diabetes, but these drugs can also cause weight gain. Quite unexpectedly, a moderate reduction of PPARgamma activity observed in heterozygous PPARgamma-deficient mice or the Pro12Ala polymorphism in human PPARgamma, has been shown to prevent insulin resistance and obesity induced by a high-fat diet. In this study, we investigated whether functional antagonism toward PPARgamma/RXR could be used to treat obesity and type 2 diabetes. We show herein that an RXR antagonist and a PPARgamma antagonist decrease triglyceride (TG) content in white adipose tissue, skeletal muscle, and liver. These inhibitors potentiated leptin's effects and increased fatty acid combustion and energy dissipation, thereby ameliorating HF diet-induced obesity and insulin resistance. Paradoxically, treatment of heterozygous PPARgamma-deficient mice with an RXR antagonist or a PPARgamma antagonist depletes white adipose tissue and markedly decreases leptin levels and energy dissipation, which increases TG content in skeletal muscle and the liver, thereby leading to the re-emergence of insulin resistance. Our data suggested that appropriate functional antagonism of PPARgamma/RXR may be a logical approach to protection against obesity and related diseases such as type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Self-citationThe hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Cellular mechanisms of insulin resistance
Shulman, G. I. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10583 · Cited by 2,714
Forman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
Kliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 3×
“Activation of PPARα pathways by HX531 or BADGE was partially abrogated in db/db mice (Figure 6a), suggesting that the RXR antagonist and the PPARγ antagonist exerted these effects, in part, through leptin signaling pathways (1, 42).”
BackgroundMethod
Cited by
Adiponectin and Adiponectin Receptors
Kadowaki, T., & Yamauchi, T. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0005 · Cited by 2,634
Self-citationden Besten, G., Bleeker, A., Gerding, A., van Eunen, K., Havinga, R., van Dijk, T. H., Oosterveer, M. H., Jonker, J. W., Groen, A. K., Reijngoud, D.-J., et al. (2015) · Diabetes · doi:10.2337/db14-1213 · Cited by 1,125
Flier, J. S. (2004) · Cell · doi:10.1016/s0092-8674(03)01081-x · Cited by 1,112
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Nuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Adiponectin regulation and function
Fang, H., & Judd, R. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170046 · Cited by 631
Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Self-citationResistin and obesity-associated insulin resistance
Steppan, C. M., & Lazar, M. A. (2002) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00522-7 · Cited by 526
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Savage, D. B., Tan, G. D., Acerini, C. L., Jebb, S. A., Agostini, M., Gurnell, M., Williams, R. L., Umpleby, A. M., Thomas, E. L., Bell, J. D., et al. (2003) · Diabetes · doi:10.2337/diabetes.52.4.910 · Cited by 430
Yannakoulia, M., Yiannakouris, N., Blüher, S., Matalas, A.-L., Klimis-Zacas, D., & Mantzoros, C. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021604 · Cited by 428
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 411
Tsuchida, A., Yamauchi, T., Takekawa, S., Hada, Y., Ito, Y., Maki, T., & Kadowaki, T. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3358 · Cited by 409
Self-citationImai, T., Takakuwa, R., Marchand, S., Dentz, E., Bornert, J.-M., Messaddeq, N., Wendling, O., Mark, M., Desvergne, B., Wahli, W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400356101 · Cited by 383
Retinaldehyde represses adipogenesis and diet-induced obesity
Ziouzenkova, O., Orasanu, G., Sharlach, M., Akiyama, T. E., Berger, J. P., Viereck, J., Hamilton, J. A., Tang, G., Dolnikowski, G. G., Vogel, S., et al. (2007) · Nature Medicine · doi:10.1038/nm1587 · Cited by 381
Retinoid X receptors: common heterodimerization partners with distinct functions
Lefebvre, P., Benomar, Y., & Staels, B. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.06.009 · Cited by 309
Genetics of Leptin and Obesity: A HuGE Review
Paracchini, V., Pedotti, P., & Taioli, E. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwi174 · Cited by 302
Frungieri, M. B., Weidinger, S., Meineke, V., Köhn, F. M., & Mayerhofer, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232422999 · Cited by 252
Modulation of RXR function through ligand design
Pérez, E., Bourguet, W., Gronemeyer, H., & de Lera, A. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.04.003 · Cited by 169
Eckertova, M., Ondrejcakova, M., Krskova, K., Zorad, S., & Jezova, D. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01037.x · Cited by 68
Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
P. Menendez-Gutierrez, M., Roszer, T., & Ricote, M. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612799436669 · Cited by 62
Okamoto, Y., Higashiyama, H., Rong, J. X., McVey, M. J., Kinoshita, M., Asano, S., & Hansen, M. K. (2007) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.02.007 · Cited by 38
Metadata
- Authors
- Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., Tsuboyama-Kasaoka, N., Yamauchi, N., Ide, T., Hori, W., Kato, S., Fukayama, M., Akanuma, Y., Ezaki, O., Itai, A., Nagai, R., Kimura, S., Tobe, K., Kagechika, H., Shudo, K., & Kadowaki, T.
- Venue
- Journal of Clinical Investigation
- Published
- 2001-10-01
- Volume
- 108
- Issue
- 7
- Pages
- 1001-1013
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2136879851
- Cited by
- 308
- References
- 58
- FWCI
- 6.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.